🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chronic Lymphocytic Leukemia
Clinical trial register · China

Chronic Lymphocytic Leukemia Trials in China

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19029 matching records held by the registry are in this view. Synced 20 Sep 2026, 17:51 UTC
19029
Studies in scope
all four open statuses
11774
Recruiting now
open to new participants
2008
Lead sponsors
across recruiting studies
Top sites
Guangzhou 17 Beijing 15 Chongqing 9 Zhengzhou 8 Fuzhou 8
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
BeOne Medicines5 Loxo Oncology, Inc.4 Ascentage Pharma Group Inc.3 Merck Sharp & Dohme LLC3 AbbVie3
Site location
Guangzhou17 Beijing15 Chongqing9 Zhengzhou8 Fuzhou8
All 41 locations
Target enrolment
to
27 of 19029 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Eli Lilly and Company
Phase 4
150
Beijing, Changsha, Guangdong, Guangzhou, Lanzhou, Nanchang, Shanghai, Taizhou
2026-03-09
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3
500
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Harbin, Zhengzhou
2026-01-22
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
500
Beijing, Fuzhou, Lanzhou, Guangzhou, Jiangmen, Nanning, Guiyang, Shijiazhuang
2025-09-04
Not yet open
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
NCT07003464Chronic Lymphocytic Leukemia
The First Hospital of Jilin University
Phase 2
30
Changchun
2025-06-15
Recruiting
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
630
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin
2025-06-11
Active, closed
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
NCT06970743Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
153
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shenzhen, Nanning
2025-05-29
Active, closed
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT06637501Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 2
94
Fuzhou, Zhengzhou, Changzhou, Nanjing, Shanghai, Hangzhou
2024-11-14
Recruiting
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
NCT06428019Chronic Lymphocytic Leukemia
AbbVie
Phase 3
170
2024-08-05
Recruiting
A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL
NCT05950997Chronic Lymphocytic Leukemia
The First Affiliated Hospital with Nanjing Medical University
Not applicable
89
Nanjin
2024-04-16
Active, closed
Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT06547944Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
30
Tianjin
2024-01-01
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Guiyang, Haikou
2023-12-13
Recruiting
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
NCT06037018Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia
CytoCares Inc
Phase 1
44
Tianjin
2023-08-07
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
2023-04-04
Active, closed
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
NCT05624554Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC
Phase 3
300
Beijing, Chongqing, Guangzhou, Guiyang, Haikou, Zhengzhou, Wuhan, Changsha
2023-03-16
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
737
Changsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Merck Sharp & Dohme LLC
Phase 2
189
Beijing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Xuzhou, Nanchang, Chuangchun
2022-07-21
Recruiting
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
NCT05147467Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ascentage Pharma Group Inc.
Phase 2
75
Guangzhou, Haikou, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin, Hanzhou
2021-12-28
Active, closed
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
309
Hefei, Beijing, Guangzhou, Wuhan, Changsha, Hohhot, Nanchang, Shenyany
2021-09-23
Active, closed
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
600
Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Hengyang
2021-09-20
Active, closed
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Loxo Oncology, Inc.
Phase 3
238
Beijing, Xicheng District, Lanzhou, Guangzhou, Haikou, Zhengzhou, Changsha, Xuzhou
2021-03-09
Recruiting
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
NCT04494503Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Ascentage Pharma Group Inc.
Phase 1/2
123
Beijing, Chongqing, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhenzhou, Wuhan
2020-08-31
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
AbbVie
Phase 3
165
2019-09-06
Active, closed
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
NCT03913949Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Ascentage Pharma Group Inc.
Phase 1
74
Hefei, Zhengzhou, Wuhan, Tianjin, Hangzhou
2019-06-03
Recruiting
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
NCT03980002Chronic Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
50
Tianjin
2019-05-15
Active, closed
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
984
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang
2019-02-25
Rows per page Showing 1–25 of 27
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-china/condition/chronic-lymphocytic-leukemia

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.